These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
    Author: Kanat O, Bagdas D, Ozboluk HY, Gurun MS.
    Journal: J BUON; 2013; 18(4):1012-8. PubMed ID: 24344031.
    Abstract:
    PURPOSE: This study was designed to evaluate the antihyperalgesic effect of CDP-choline (cytidine-5'-diphosphate- choline; citicoline) in a rat model of neuropathic pain produced by oxaliplatin (OXA). METHODS: A single administration of OXA (6 mg/kg intraperitoneally/ ip) was used for induction of neuropathy. We assessed the antihyperalgesic effect of intracerebroventricularly (icv) administered CDP-choline (0.5, 1.0 and 2.0 μmol) using the rat paw pressure test (Randall-Selitto). RESULTS: CDP-choline significantly reduced OXA-induced mechanical hyperalgesia, in a dose- and time-dependent manner. The antihyperalgesic effect of CDP-choline was blocked by the neuronal high affinity choline uptake inhibitor hemicholinium-3 (1 μg; icv), the nonselective nicotinic receptor antagonist mecamylamine (50 μg; icv), the α7 selective nicotinic acetylcholine receptor antagonist α-bungarotoxin (2 μg; icv), and the gamma-amino butyric acid (GABA)-B receptor antagonist CGP-35348 (20 μg; icv), but not by the nonselective opioid receptor antagonist naloxone (10 μg; icv) and the nonselective muscarinic receptor antagonist atropine (10 μg; icv). CONCLUSION: These findings indicate that CDP-choline exerts an antihyperalgesic effect in OXA-induced neuropatic pain and it can be tested in clinical trials.
    [Abstract] [Full Text] [Related] [New Search]